Iran’s Ministry of Health and the Japan International Cooperation Agency (JICA) have signed a Memorandum of Unders...
A team of scientists at Nagoya University, Japan has introduced substituted warped nanographene, which is soluble i...
Researchers from Shinshu University have found that, unlike conventional plates, the titanium fiber plates do not cause ...
Singapore – Takeda has started a new initiative aimed at helping inflammatory bowel disease patients sort thr...
YL Biologics (YLB), a joint venture by drugmaker Lupin and Yoshindo, has successfully completed the late phase clinical ...
Scottish firm TC BioPharm has inked a strategic collaboration with the Japan’s NIPRO Corporation to co-d...
The Japan Prize Foundation has announced Max D. Cooper, MD, as a laureate of the 2018 Japan Prize. Cooper will receive a...
Researchers at Florey Institute of Neuroscience and Mental Health, and University of Melbourne, Australia and Japanese N...
A team of researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, has report...
BiomX Ltd., a microbiome company, announced that it has exclusively sub-licensed a set of bacterial targets from JSR Cor...
A team of experts at the University of Tokyo's Institute of Industrial Science (IIS) has developed a new probe that coul...
Hitachi, Ltd. and Hokkaido University announced that it has obtained U.S. Food & Drug Administration (FDA) 510(k) cl...
Tokyo based Astellas Pharma Inc. recently announced the acquisition of Mitobridge, Inc. Astellas paid $225 million to ac...
Sato Pharmaceutical Co., Ltd. has obtained marketing and manufacturing approval for the oral antifungal agent, Nailin ca...
Telix Pharmaceuticals , an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic...
Storm Therapeutics, a Cambridge Life Sciences firm has attracted an additional £4m cash injection to its £12...
Takeda Pharmaceutical is planning to acquire Belgian biopharmaceutical venture TiGenix with an aim of strengthening...
Alexion Pharmaceuticals, recently bagged approval for its key candidate Soliris (eculizumab) fromthe Ministry of Health,...
